The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of 27-gene IO score with outcome in a phase Ib trial of pembrolizumab (pembro) plus chemotherapy (CT) in metastatic triple-negative breast cancer (mTNBC).
 
David B. Page
Honoraria - Novartis
Consulting or Advisory Role - Biotheranostics; Brooklyn ImmunoTherapeutics; Genentech; Lilly; Merck; Novartis; Puma Biotechnology; Roche; Sanofi
Speakers' Bureau - Genentech; Novartis; Roche
Research Funding - Bristol-Myers Squibb; Brooklyn ImmunoTherapeutics; MedImmune; Merck; WindMIL
Expert Testimony - Vincent Davey Law Firm
 
Krystle Louise Collins
No Relationships to Disclose
 
Venkatesh Rajamanickam
No Relationships to Disclose
 
Nicole Moxon
Consulting or Advisory Role - Seagen
 
Staci L. Mellinger
No Relationships to Disclose
 
Alison Katherine Conlin
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Novartis; Pfizer; Seattle Genetics/Astellas
Speakers' Bureau - Seagen
 
Robert Seitz
Employment - OncoCyte
Leadership - OncoCyte
Stock and Other Ownership Interests - OncoCyte
Consulting or Advisory Role - Thermo Fisher Scientific
 
Kim McGregor
Employment - Foundation Medicine; OncoCyte
Stock and Other Ownership Interests - Genentech; OncoCyte; Roche
 
Tyler J. Nielsen
Employment - OncoCyte
Patents, Royalties, Other Intellectual Property - International Appln. No.: PCT/US21/44240 Title: CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS Applicant: Oncocyte Corporation Filed: August 2, 2021 Earliest Priority Claim: US Appln. No. 63/060,321; Filed: August 3, 2020 (Inst)
 
Heather L. McArthur
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Genomic Health; Immunomedics; Lilly; Merck; Pfizer; Puma Biotechnology; Puma Biotechnology; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); ZIOPHARM Oncology (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; DAVA Pharmaceuticals; Genentech; Immunomedics; Lilly; Lilly; Lilly; Lilly; Merck; Pfizer; Puma Biotechnology; Spectrum Pharmaceuticals
Other Relationship - Genomic Health; Lilly